| Objective:The efficacy of the treatment of advanced (IIIB and IV) non-small cell lung cancer(NSCLC) observed and compared gemcitabine in combination with cisplatinnorcantharidin sodium and the efficacy of gemcitabine and cisplatin in the treatment ofadvanced NSCLC with or without differences, and both the chemotherapy side effects:After chemotherapy, neutropenia, thrombocytopenia, elevated serum transaminases andserum urea nitrogen after chemotherapy with or without a difference. Provide new methodsand theoretical basis for clinical treatment of advanced (IIIB and IV) NSCLC, in order toimprove the efficacy of advanced NSCLC patients, reduce patient suffering, and prolongthe patient’s life.180patients were divided into treatment group and observation group (n=90cases), case-control study.Methods:Advanced (IIIB and IV) hospitalization in Laiwu City Chinese MedicineHospital in2010.1-2012.2,180cases of NSCLC patients, the patients were diagnosed bychest CT, and pathology, all cases Karnofsky score≥70points.180patients withsquamous cell carcinoma in68cases,92cases of adenocarcinoma, large cellundifferentiated carcinoma in20cases, IIIB106cases,74cases of stage IV.⑴treatmentgroup method:28days for a period, respectively, at1,2,3-day intravenous infusion ofcisplatin30mg/m2+NS250ml;1,8,15-day intravenous infusion of gemcitabine1000mg/m2+NS250ml (30minutes);1-21day intravenous infusion of norepinephrinecantharidin sodium injection250ml:2.25g (sodium chloride)-30mg (norepinephrinecantharidin prime).⑵control group treatment:28days for a period, respectively, at1,2,3-day intravenous infusion of cisplatin30mg/m2+NS250ml;1,8,15-day intravenousinfusion of gemcitabine1000mg/m2+NS250ml (30minutes). The two groups of patients after three cycles of treatment efficacy evaluation.Results:⑴Efficiency: The treatment group was92.2%, the control group was80%, thedifference was statistically significant (P <0.0055).⑵Leukopenia after chemotherapy(I-IV): The treatment group was46.67%,85.56%in the control group, the difference wasstatistically significant (P <0.001).⑶Chemotherapy thrombocytopenia (I-IV): Thetreatment group was50%in the control group was84.45%, the difference was statisticallysignificant (P <0.001).⑷Transaminase changes after chemotherapy, the treatment groupwas24.45%,51.11%in the control group, the difference was statistically significant (P<0.0033).(5) BUN changes after chemotherapy, the treatment group,11.11%,26.67%ofthe control group, the difference was not statistically significant (P=0.7981).(6) Treatmentgroup compared significantly improved efficacy with in the control group and significantlyreduced some of the side effects, Little significant improvement in any side effects, Theprogram improve patients’ tolerance to chemotherapy, gemcitabine and cisplatin andnorcantharidin sodium treatment of advanced NSCLC,The program is worthy of clinicalapplication.Conclusion:（1）The effective rate of the treatment group was significantly better than the controlgroup, the effective rate of the treatment group was92.2%, the effective rate of controlgroup is about80%, the difference between the two groups was statistically significant (P<0.05).（2）After chemotherapy leukopenia, thrombocytopenia and increased serumtransaminase, the treatment group was significantly better than the control group, thedifference between the two groups were statistically significant (P <0.001).（3）Afterchemotherapy, elevated blood urea nitrogen, the treatment group was less than in thecontrol group, but no statistical significance (P=0.7981). In short, the efficiency of thetreatment group is obviously improved than the control group. part of the side effects ofchemotherapy reduces obviously, improve the patient ’s resistance to chemotherapy; part ofthe side effects of chemotherapy improved, attention should be paid to the protection ofrenal function in patients. Gemcitabine and cisplatin combined with norcantharidin sodiumfor advanced NSCLC plan is worth to popularize in the clinical application. |
PDF Full Text Request